Cargando…

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO) alters inflammation and favors T-cell tolerance in cancer, but the underlying molecular mechanisms remain poorly understood. The integrated stress response kinase GCN2, a sensor of uncharged tRNA that is activated by amino acid deprivation,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metz, Richard, Rust, Sonja, DuHadaway, James B., Mautino, Mario R., Munn, David H., Vahanian, Nicholas N., Link, Charles J., Prendergast, George C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525601/ https://www.ncbi.nlm.nih.gov/pubmed/23264892 http://dx.doi.org/10.4161/onci.21716

Ejemplares similares

IDO1 is an Integral Mediator of Inflammatory Neovascularization
por: Mondal, Arpita, et al.
Publicado: (2016)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease
por: Sucher, Robert, et al.
Publicado: (2010)

IDO-induced immunosuppressive tryptophan catabolism following primary HIV infection
por: Jenabian, Mohammad-Ali, et al.
Publicado: (2014)

Tryptophan Feeding of the IDO1-AhR Axis in Host–Microbial Symbiosis
por: Zelante, Teresa, et al.
Publicado: (2014)

Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
por: Günther, Juliane, et al.
Publicado: (2019)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells
por: Lewis, Holly C., et al.
Publicado: (2017)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

Design, synthesis and evaluation of tryptophan analogues as tool compounds to study IDO1 activity
por: Cundy, Nicholas J., et al.
Publicado: (2021)

Psychological Stress-Induced, IDO1-Dependent Tryptophan Catabolism: Implications on Immunosuppression in Mice and Humans
por: Kiank, Cornelia, et al.
Publicado: (2010)

Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
por: Kim, Minah, et al.
Publicado: (2021)

Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
por: Zhai, Lijie, et al.
Publicado: (2021)

USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
por: Shi, Dongni, et al.
Publicado: (2022)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
por: Brincks, Erik L., et al.
Publicado: (2020)

IL4i1 and IDO1: Oxidases that control a tryptophan metabolic nexus in cancer
por: Zeitler, Leonie, et al.
Publicado: (2023)

1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis
por: Wei, Chunyan, et al.
Publicado: (2016)

IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma
por: Folgiero, Valentina, et al.
Publicado: (2016)

Electroacupuncture Relieves LPS-Induced Depression-Like Behaviour in Rats Through IDO-Mediated Tryptophan-Degrading Pathway
por: Zhang, Kun, et al.
Publicado: (2020)

Exogenous Tryptophan Promotes Cutaneous Wound Healing of Chronically Stressed Mice through Inhibition of TNF-α and IDO Activation
por: Bandeira, Luana Graziella, et al.
Publicado: (2015)

Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells
por: Newman, Alice Clare, et al.
Publicado: (2021)

Cang-Ai Volatile Oil Ameliorates Depressive Behavior Induced by Chronic Stress Through IDO-Mediated Tryptophan Degradation Pathway
por: Zhang, Kailing, et al.
Publicado: (2021)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Chronic Treatment with the IDO1 Inhibitor 1-Methyl-D-Tryptophan Minimizes the Behavioural and Biochemical Abnormalities Induced by Unpredictable Chronic Mild Stress in Mice - Comparison with Fluoxetine
por: Laugeray, Anthony, et al.
Publicado: (2016)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
por: Nayak-Kapoor, Asha, et al.
Publicado: (2018)

Host cell depletion of tryptophan by IFNγ-induced Indoleamine 2,3-dioxygenase 1 (IDO1) inhibits lysosomal replication of Coxiella burnetii
por: Ganesan, Sandhya, et al.
Publicado: (2019)

Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan
por: Zhang, Xiaolong, et al.
Publicado: (2017)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
por: Zakharia, Yousef, et al.
Publicado: (2021)

Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer
por: DuHadaway, James, et al.
Publicado: (2016)

Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
por: Sari, Suat, et al.
Publicado: (2019)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
por: Duan, Zhenzhen, et al.
Publicado: (2020)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Tryptophan-kynurenine pathway attenuates β-catenin-dependent pro-parasitic role of STING-TICAM2-IRF3-IDO1 signalosome in Toxoplasma gondii infection
por: Majumdar, Tanmay, et al.
Publicado: (2019)

Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2
por: Tijono, Sofian M, et al.
Publicado: (2022)

IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation
por: Muller, Alexander J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ec2mnga4bcnqa7a4qrbjs983uv